Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

El-Helou said that patent expiries in the US alone represent $236bn in revenue at risk between 2025 and 2030. Image credit: Abigail Beaney / GlobalData. AI will be a useful tool in reducing R&D costs ...

Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

GlobalData’s analyst consensus forecast for gedatolisib is set to generate $827m in 2031. Credit: Jo Panuwat D/Shutterstock.com. At the European Society for Medical Oncology (ESMO) 2025 event, held in ...

Moderna will discontinue the development of mRNA-1647 in CMV after the trial failure. Image credit: Tada Images / Shutterstock.com. Moderna is terminating the development of an mRNA vaccine in ...